ST Renfu announced that Yichang Renfu Pharmaceutical Co., Ltd., a holding subsidiary of the company, recently received the “Notice of Acceptance” for drug registration and marketing license applications for brixetam tablets approved and issued by the State Drug Administration. The registration classification is 3 types of chemicals. The application indications are single drug treatment and additive treatment for partial seizures in patients aged 16 and above. Up to now, Yichang Renfu has invested about 37 million yuan in R&D on this project. The acceptance of the application marks that the registration of this domestically produced drug has entered the review stage. If successfully passed through the review and approval, it will enrich the company's product line.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.